Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...

A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...

Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may ...

Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, ...

Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

Having inactive secondary progressive multiple sclerosis can be confusing. Relapses may stop, but symptoms persist. Get ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Briumvi is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.

Fasting and ketogenic diets were found to benefit blood fats, weight, and blood pressure in MS, but did not reduce brain ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...